Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). APG4 is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE) conjugated form, and has the capacity for the binding to autophagosomes.

Target	Autophagy Related 4C Cysteine Peptidase (ATG4C)
Reactivity	Human, Mouse
Host	Rabbit
Clonality	Polyclonal
Tested Applications	WB, IHC
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Immunogen	KLH-conjugated synthetic peptide between 419-448 amino acids from the C-terminal region of human ATG4C.
Purification	Purified Rabbit Polyclonal Antibody.
Isotype	IgG
Conjugation	Unconjugated
Storage	Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
Swiss Prot	Q96DT6
NCBI Accession	NP_116241.2 NP_835739.1
Buffer	PBS containing 0.09% sodium azide.
UNSPSC Code	12352203
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.